Clinical Trials Logo

Filter by:
NCT ID: NCT05981950 Recruiting - Clinical trials for Artificial Intelligence

Real-world of AI in Diagnosing Retinal Diseases

Start date: August 1, 2023
Phase:
Study type: Observational

The objective of this study is to apply an artificial intelligence algorithm to diagnose multi-retinal diseases in real-world settings. The effectiveness and accuracy of this algorithm are evaluated by sensitivity, specificity, positive predictive value, negative predictive value, and area under curve.

NCT ID: NCT05981703 Recruiting - Solid Tumor Clinical Trials

A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors

Start date: September 7, 2023
Phase: Phase 1
Study type: Interventional

This is an open-label, multicenter, and nonrandomized dose escalation and dose expansion study to evaluate BGB-26808 as monotherapy or in combination with tislelizumab in participants with advanced solid tumors. The main purpose of this study is to explore the recommended dosing for BGB-26808.

NCT ID: NCT05981677 Recruiting - Risk-Taking Clinical Trials

Social Feedback and Dysfunctional Risk Taking in NSSI Adolescents

Start date: December 6, 2023
Phase:
Study type: Observational

Nonsuicidal self-injury (NSSI) is defined as direct, intentional physical injury without suicidal intention. Problematic interpersonal relationships and decision-making have been demonstrated to play crucial roles in this maladaptive behavior, especially for adolescents. Accumulating evidence suggests that decision processes and risk-taking are strongly influenced by the affective state of the individual. However, whether these interactions are disrupted in NSSI adolescents has not been systematically examined. In the current study, the investigators modified one of the most widely used paradigms for measuring an individual's risk decision-making, the Balloon Analogue Risk Task (BART). The investigators combine social reward (green balloon), punishment (red balloon), and control feedback (yellow balloon), to investigate whether the NSSI adolescents have dysfunctional risk-taking behavior while facing different social outcomes. The investigators recruit one group of NSSI adolescents (n = 40) and one health control (HC) group (n = 40), to compare their risk-related decisions during the emotional BART. The investigators hypothesize that compared to HC, NSSI adolescents will show altered effects of social reward and punishment on risk-related decision-making, in particular higher risk avoidance in the context of social punishment.

NCT ID: NCT05981651 Recruiting - Facial Palsy Clinical Trials

Development and Application of a Dynamic Three-dimensional Quantitative Facial Measurement Device

Start date: July 1, 2022
Phase:
Study type: Observational

The aim of this project is to successfully develop and industrialise the "Facial Movement 3D Dynamic Quantitative Measurement Device", which is a commercial device that can provide dynamic indicators of facial movement, and can practically solve the evaluation problems of facial paralysis for doctors and patients, and has important clinical value and social benefits.

NCT ID: NCT05981612 Recruiting - Clinical trials for Nonsuicidal Self Injury

Impact of Emotional Reactivity on Dysfunctional Decision-Making in NSSI Adolescents

Start date: December 6, 2023
Phase:
Study type: Observational

Nonsuicidal self-injury (NSSI) is defined as direct, intentional physical injury without suicidal intention. Studies revealed that dysfunctional interpersonal relationships and reward-related decision-making may play crucial roles in this maladaptive behavior, especially in adolescents. These interpersonal decision contexts are characterized by constant updating of expectations of rewards and the actual received rewards as well as the associated emotional reactions. These processes have recently been computationally formalized as prediction errors (PE), specifically reward PEs, valence PEs, and arousal PEs (Heffner et al., 2021; Nat Hum Behav). In the current study, the investigators aim to investigate whether these PEs make discernible contributions to social decisions in the context of unfair experiences among adolescents with NSSI and matched healthy control adolescents (HC). Specifically the investigators hypothesized that: 1) reward and emotional PEs show significant predictions of punishment decisions in both groups, 2) however, compared to HC adolescents, the NSSI group will exhibit selective dysfunctions in emotional but not reward PEs leading to punish a norm proposer who provided unfair offers.

NCT ID: NCT05981235 Recruiting - Clinical trials for Gastrointestinal Tumors

Phase 1 Trial of AZD6422 in CLDN18.2+ GI Tumors

Start date: December 14, 2023
Phase: Phase 1
Study type: Interventional

This is a FTiH, Phase 1 IIT to evaluate the safety, feasibility, cellular kinetics (CK), pharmacodynamics (PD), immunogenicity, and preliminary antitumor activity of AZD6422 in adult participants with advanced or metastatic CLDN18.2+ GI tumors.

NCT ID: NCT05981157 Recruiting - Clinical trials for Nasopharyngeal Carcinoma

Anrotinib and Tirelizumab in First-line Treatment of RM-NPC

Start date: June 1, 2023
Phase: Phase 2
Study type: Interventional

This is a prospective phase II clinical trial to evaluate the efficacy and safety of Anrotinib and Tirelizumab as a first-line treatment in patients with advanced recurrent or metastatic nasopharyngeal carcinoma.

NCT ID: NCT05981079 Recruiting - Clinical trials for Late-Onset Neonatal Sepsis

Model-based Dose Versus Empirical Dose of Piperacillin/Tazobactam in Preterm Neonates With Late-onset Sepsis.

PIP/TAZO
Start date: July 31, 2023
Phase: Phase 4
Study type: Interventional

This study aims to compare the clinical outcomes, safety and PD target attainment of the model-based dose and empirical dose of piperacillin/tazobactam in the treatment of LOS in premature neonates, so as to optimize the piperacillin/tazobactam dose regimen.

NCT ID: NCT05981066 Recruiting - Clinical trials for Advanced Hepatocellular Carcinoma

A Clinical Study of mRNA Vaccine (ABOR2014/IPM511) in Patients With Advanced Hepatocellular Carcinoma

Start date: July 10, 2023
Phase: N/A
Study type: Interventional

This is an open label, single-site, investigator-initiated trial designed to evaluate the safety, tolerability and preliminary efficacy of ABOR2014(IPM511) injection in relapsed/ refactory HCC.

NCT ID: NCT05981014 Recruiting - Breast Neoplasms Clinical Trials

Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes as Neoadjuvant Therapy for HER2-Negative Breast Cancer

Start date: August 1, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

RATIONALE: Patients with HER2-negative breast cancer not responding to initial neoadjuvant chemotherapy might have lower chances for a pathologic complete response (pCR) at definitive surgery, indicating worse prognosis. Adoptive cell therapy has demonstrated efficacy in advanced breast cancer, but whether the addition of adoptive cell therapy to neoadjuvant chemotherapy could increase the pCR rate remains unclear. Tumor-draining lymph node-derived lymphocytes (LNLs) that have abundant tumor-reactive T cells, but not exhausted T cells, are easy to produce. It is not yet known whether LNL treatment is safe and effective in patients with HER2-negative breast cancer not responding to neoadjuvant chemotherapy. PURPOSE: This open-label phase I/II trial is to investigate the safety and efficacy of autologous LNL in patients with HER2-negative breast cancer not responding to neoadjuvant chemotherapy.